Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.06 AUD | +0.07% | +1.14% | -5.88% |
Apr. 29 | Clinuvel Pharmaceuticals Obtains Orphan Drug Designation in Europe for Xeroderma Pigmentosum Treatment; Shares Up 3% | MT |
Mar. 14 | Clinuvel Pharmaceuticals Launches Share Buyback Program | MT |
Sales 2024 * | 89.47M 57.97M | Sales 2025 * | 98.61M 63.89M | Capitalization | 754M 489M |
---|---|---|---|---|---|
Net income 2024 * | 34M 22.03M | Net income 2025 * | 37M 23.97M | EV / Sales 2024 * | 6.34 x |
Net cash position 2024 * | 187M 121M | Net cash position 2025 * | 219M 142M | EV / Sales 2025 * | 5.42 x |
P/E ratio 2024 * |
22
x | P/E ratio 2025 * |
20.3
x | Employees | - |
Yield 2024 * |
0.45% | Yield 2025 * |
0.5% | Free-Float | 79.56% |
Latest transcript on Clinuvel Pharmaceuticals Limited
1 day | +0.07% | ||
1 week | +1.14% | ||
Current month | +4.87% | ||
1 month | -3.46% | ||
3 months | -2.52% | ||
6 months | +1.55% | ||
Current year | -5.88% |
Managers | Title | Age | Since |
---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 61 | 05-10-31 |
Darren M. Keamy
DFI | Director of Finance/CFO | - | 05-10-31 |
Lachlan Hay
COO | Chief Operating Officer | - | 06-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 61 | 05-10-31 |
Director/Board Member | - | 07-02-05 | |
Karen Agersborg
BRD | Director/Board Member | - | 18-01-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-01 | 15.06 | +0.07% | 70 978 |
24-04-30 | 15.05 | -1.76% | 33,809 |
24-04-29 | 15.32 | +5.15% | 77,127 |
24-04-26 | 14.57 | -2.80% | 54,613 |
24-04-24 | 14.99 | +0.67% | 106,329 |
Delayed Quote Australian S.E., May 01, 2024 at 02:10 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.88% | 490M | |
-4.24% | 86.85B | |
+2.76% | 40.16B | |
-16.98% | 31.28B | |
+57.86% | 25.27B | |
-16.24% | 15.33B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
-17.10% | 11.69B | |
+6.89% | 8.83B |
- Stock Market
- Equities
- CUV Stock